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The lack of a proper animal model has impeded understanding of the molecular mechanism of leukemia
associated with the MLL-AF4 fusion. In this issue of Cancer Cell, Krivtsov et al. report a much-improved
murine Mll-AF4 model and propose a molecular link with H3K79 methylation mediated by the histone meth-
yltransferase DOT1L.The mixed-lineage leukemia (MLL) gene,
which encodes a histone methyltransfer-
ase, can rearrange with more than 50 dif-
ferent fusion partners in multiple-lineage
leukemias, i.e., acute myeloid leukemia
(AML), acute lymphoblastic leukemia (ALL),
and acute biphenotypic leukemia (ABL).
Whilemousemodeling has been extremely
successful in reconstructing myeloid
disease, progress in developing ALL and
ABL models for MLL has been rather
limited.
MLL fusions such as MLL-ENL can tar-
get either committed murine myeloid pro-
genitors (common myeloid progenitors or
granulocyte macrophage progenitors) or
hematopoietic stemcells (HSCs) to induce
AML but fail to give rise to ALL or ABL
(Cozzio et al., 2003).Multilineage leukemia
has been achieved by targeting multipo-
tent HSCs, but not myeloid progenitors,
using MLL-GAS7, suggesting that both
the origin of the leukemic stem cells and
the MLL fusion partners play important
roles in determining the disease pheno-
type (So et al., 2003). An instructive role
of fusion partners in directing lineage
specificity is further supported by findings
from translocator models, where T lym-
phoid to myeloid lineage reassignment
was observed only in cells carrying MLL-
ENL, but not MLL-AF9, even though both
were expressed under the same condi-
tions (Drynan et al., 2005).
An animal model for the most common
MLL fusion, MLL-AF4, which uniquely
associates with ALL/ABL, is still missing.
Using conventional knockin or conditional
invertor approaches,Mll-AF4 is capable of
inducing lymphoid malignancy with pro-
tracted latency (Chen et al., 2006; Metzler
et al., 2006). However, the disease is pre-
dominately limited to mature B cell lym-phoma, which is very different from pro-
B ALL/ABL in humans. The lack of proper
MLL-AF4diseasemodels has significantly
impeded progress in understanding the
underlying mechanisms for this fusion.
Reconstructing a MLL-AF4 Model
and Its Corrupted Epigenetic
Networks
In this issue ofCancer Cell, Armstrong and
colleagues establish a much-improved
Mll-AF4diseasemodel using a conditional
expression approach wherein the human
AF4 cDNA is inserted into the murine Mll
exon 8, downstream of a transcriptional
stop site flanked by LoxP sites, providing
important molecular insights into MLL-
AF4 pathogenesis (Krivtsov et al., 2008).
They demonstrate that bone marrow cells
expressing Mll-AF4 after retroviral Cre
transduction have enhanced serial lym-
phoid replating ability and can inducemul-
tilineage leukemia following bone marrow
transplantation.
Multilineage leukemia also occurred in
this model when Mll-AF4 was conditionally
expressed by crossing Mll-AF4 mice with
Mx1-Cremice. Over half of these mice de-
veloped AML. However, about 40% of the
micedevelopedBcellALL, inwhichthema-
jority were B220+CD19+Mac1 with clonal
DJH rearrangements, with a few cases of
pro-B cell-like ALL (B220+CD19Mac1
with clonal DJH rearrangements). Interest-
ingly, there were also three ABL cases co-
expressing lymphoid (B220) and myeloid
(Mac1) markers with or without immuno-
globulin gene rearrangement. When com-
paring the frequency of leukemia-initiating
cells (LICs) by limitingdilution transplant ex-
periments, MLL-induced ALL had at least
a 10-fold higher frequency of LICs than
MLL-induced ABL.Cancer Cell 14,The murine Mll-AF4-induced ALL
model and human MLL-rearranged ALLs
shared a similar gene expression signa-
ture and a significant enrichment of the
H3K79me2 histone modification mark in
the HoxA cluster and other specific loci
as compared with their normal counter-
parts. Moreover, the specific H3K79me2
profile was also sufficient to distinguish
human MLL-rearranged ALL from MLL-
germline ALL. The H3K79me2 mark
associated with active transcription is
specifically conferred by theH3K79meth-
yltransferase DOT1L, which has previ-
ously been implicated in MLL-AF10 path-
ogenesis. When the expression of DOT1L
in two different MLL-AF4 cell lines was
downregulated using shRNAs, it reduced
not only the H3K79me2 mark but also
the expression of theHOXA cluster, which
is believed to be a critical downstream
target for MLL fusions. These results
suggest that DOT1L may be a potential
therapeutic target for MLL-AF4 leukemia.
Are We Missing the Real Cellular
Targets?
The report by Armstrong and colleagues
(Krivtsov et al., 2008) provides novel in-
sights into MLL-AF4 pathogenesis but
also raises two longstanding and unan-
swered questions: (1) What determines
the lineage specificity of MLL, and (2)
can we target epigenetic enzymes that
associate with MLL fusions for leukemo-
genic suppression?
Although the Krivtsov et al. study pro-
vides the long sought-after B-ALL pheno-
type, MLL-AF4 in human leukemia almost
exclusively associates with early pro-B or
biphenotypic leukemia, which is quite dif-
ferent from the murine model, in which
over half of the mice developed AML.November 4, 2008 ª2008 Elsevier Inc. 345
Cancer Cell
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Wild-type MLL (MLL-C and MLL-N) encoding a H3K4 histone methyltransferase mediates regulated gene
expression via dynamic recruitment of transcription complexes. As a result of gene rearrangement in leu-
kemia, MLL fusions (MLL-X and MLL-Y) recruit different transcriptional complexes containing new his-
tone-modifying enzymes such asDOT1L (e.g., MLL-AF4) and PRMT1 (e.g., MLL-EEN), resulting in deregu-
lated gene expression. It has already been shown that specific knockdown of these histone modification
enzymes or abrogation of their catalytic activities inhibits MLL-mediated transformation. Although further
studies are needed to determine the actual therapeutic window, development of small-molecule inhibitors
targeting the rigid catalytic domain of these enzymes specifically recruited by MLL fusions represents
a promising avenue for targeting these oncogenic transcription factors. (Illustration by Pui Yi Tse.)Other unique features of human MLL-AF4
leukemia, including its remarkably short
latency and specific association with
FLT3 deregulation/mutation, are not dis-
cussed in the report. However, the over-
whelming number of AMLs argues against
an instructive role of AF4 in defining the
B-ALL phenotype. An alternative but not
mutually exclusive explanation is that the
MLL-AF4 model may have missed the
‘‘real targets.’’ The majority of murine
Mll-AF4 ALLs were more mature pre-B
cell-like ALL, which is different from the
human MLL-AF4 early pro-B ALL/ABL. It
is not clear what cells (e.g., HSCs versus346 Cancer Cell 14, November 4, 2008 ª20progenitors) were targeted in this MLL-
AF4 model, as cellular fractionation ex-
periments were not performed. However,
the described multilineage leukemia is
highly reminiscent of the one reported
for MLL-GAS7 when multipotent HSCs
were targeted (So et al., 2003), suggesting
multipotent hematopoietic stem/progeni-
tor cells as potential targets. Notably,
the specific association of human MLL-
AF4 ALL/ABL with neuron-glial antigen 2
(NG2) expression and the backtracking
of MLL-AF4 clones to the prenatal
stage suggest a very early developmental
origin of the target cells (Gale et al.,08 Elsevier Inc.1997). On the other hand, the microenvi-
ronment of the host may also influence
the disease phenotype, as described
recently for MLL-ENL and MLL-AF9 in
the humanized model (Barabe et al.,
2007; Wei et al., 2008). Thus, future stud-
ies using murine or humanized MLL
models should provide further insights
into this critical issue.
Targeting the Untargetable
MLL leukemias, in particular patients
with MLL-AF4, respond poorly to current
cancer therapeutics; therefore, develop-
ment of more effective and specific reg-
imens is urgently needed. While directly
targeting an oncogenic transcription fac-
tor has proven to be difficult, emerging
evidence indicates that MLL fusions acti-
vate downstream target genes via spe-
cific recruitment of histone modification
enzymes, which can be potential thera-
peutic targets. DOT1L and PRMT1, two
distinctive histone modification enzymes
mediating H3K79 and H4R3 methylation,
respectively, have been independently
linked to MLL-mediated pathogenesis
(Cheung et al., 2007; Okada et al.,
2005). Direct fusion of PRMT1 or part
of DOT1L to truncated MLL is sufficient
to transform primary hematopoietic cells,
and the transformations are dependent
on the catalytic activity of these en-
zymes. Moreover, downregulation of
PRMT1 expression can specifically sup-
press transformation mediated by cer-
tain MLL fusions but not E2A-PBX, re-
vealing the potential of targeting
specific epigenetic modifying enzymes
for cancer therapeutics (Cheung et al.,
2007). The current study by Armstrong
and colleagues (Krivtsov et al., 2008)
demonstrating the significance of
DOT1L and the associated histone mark
for disease classification and activation
of critical downstream targets further en-
dorses this idea (Figure 1). However, it is
notable that DOT1L recruitment is ubiqui-
tously associated with gene transcription
and that a critical level of DOT1L is re-
quired for general cell survival (Okada
et al., 2005). Reduction of mDOT1L by
over 70% results in growth arrest and
apoptosis in both hematopoietic and
nonhematopoietic cells. Knocking down
mDOT1L expression by just 50% inhibits
primary transformed cells regardless of
the interaction between DOT1L and the
MLL fusions. Thus, the apparently
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in multiple cell types may limit its thera-
peutic potential unless a specific thera-
peutic window can be identified to distin-
guish normal versus leukemic cells.
However, the emerging identification of
the epigenetic networks and modifying
enzymes deregulated by MLL fusions will
no doubt continue to provide novel in-
sights and therapeutic avenues to target
these classically nondruggable oncopro-
teins (Figure 1).
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